Member Info for Aether

Will this come out in the deep dive?

If the data from the deep dive, Actv-2 P2 or Long Covid is good.

The variant agnostic nature will be attractive to any larger pharmaceutical company.

Great posts, Titania!

Don't feed his insanity.

Green bin it.

How many patients didn't have steroids?

Interesting. SNG could make a big difference in thes circumstances.

If this happens, it will be under the auspices of another company.

A green box. I recommend it.

Why is it taking so long?

Are there any patients that didn't have steroids?

Beforegolf alluded to statistical techniques to take this and other confounding factors into account in the deep dive analysis when calculating statistical significance for specific sub-categories of patients.
He stated he had talked to an A&E consultant about this.

But with good Long Covid data and statistical signifiance shown in other categories.

Thanks for the reply. The question was:

Is there a possibility of a TO or JV without an immediate EUA?

Is there a possibility of a TO or JV without an immdediate EUA?

I just want to salvage some of the investment.
This seems possible.
The post by BeforeGolf inspired some confidence about the deep dive data, etc.
The drug works but another company is needed to bring it to market.
This will take a few months.

It will still be a challange to get an EUA given the surrounding circumstances.

Good deep dive, Activ-2 P2, Long Covid data will lead to a TO or JV and extrication from the share.

I have no interest in waiting for the BoD to **** ** another trial and I don't think Polygon would allow them.

It will take a few months.

Greenbox it.

It's insanity wants attention.

That's why it posts.

2009? No.

Tommy - the next three months will be critical.

- getting on another trial(s). A large enough trial is critical. Preferably designed by new people.
- SPRINTER P3 deep dive and long Covid analysis throw up some gems.
- ACTIV-2 P2 data being very good.
- Long Covid data. This is critical.

The drug works.

Patience is key.

The case that Interferons work is further proved in the success of Eiger.

Once there is evidence this drug can be brought to market a TO or JV is the best option to extricate from this share.